Nuvalent (NASDAQ: NUVL) up 35% on lung cancer trial results - next info Oct 13th

Nuvalent (NASDAQ: NUVL) stock is up 35% on the announcement that one of its lung cancer therapies has reported decent results. This is good, obviously, a pharma development company reports good news about a pharma development is good news. It’s also worth pointing out that this is a long way from being something that can be sold, or even approved for sale. There’s also that little psychological issue about stock markets - that often enough it’s worth buying the rumour and then selling the fact.

As background: “Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development;” and so on.

More specifically, the announcement here: “NVL-655 is currently being evaluated in the ALKOVE-1 Phase 1/2 clinical trial, a first-in-human study of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors (NCT05384626). The Phase 1 dose escalation portion is enrolling ALK-positive NSCLC patients who have previously received at least one ALK TKI and patients with other ALK-positive solid tumors who have been previously treated with at least one prior systemic anticancer therapy.”

OK, so it’s working in as far as a Phase I test tells us something is working. But there are years yet (Phase II, Phase III tests) before this is something that can actually be sold, even if it does pass all those tests. That 35% price rise is of the order of $600 million added to the market capitalisation which is a lot at this stage.

Nuvalent graph

Nuvalent stock price from Google Finance

The next information release: “Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 at the 35th AACR-NCI-EORTC (ANE) Symposium taking place October 11-15, 2023, in Boston, Massachusetts.” It’s actually going to be the 13th, with an investor call and so on to follow.

Now, calling such things is difficult. But it is often enough true that people get terribly excited by such breakthroughs - to then realise that they’re going to take a long time, aren’t immediately profitable and so on. Which is what leads to that stock market idea of buy the rumuor, sell the fact. Too much hope gets built into the price before the actual news gets released.

We’d not say we insist this is going to happen here, that the Nuvalent stock price will wilt on the actual announcement. But let’s say we’d not be surprised if it does.